ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS IN THE TREATMENT OF HYPERTENSION
ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS IN THE TREATMENT OF HYPERTENSION
复制标题
DOI：
10.1097/00005344-199100180-00002
复制
发表时间：
1991-01-01
影响因子：
3
通讯作者：
MANCIA, G
中科院分区：
文献类型：
--
作者：
MANCIA, G
本文探讨了血管紧张素转换酶（ACE）抑制剂作为一线抗高血压药物的证据。ACE抑制剂与传统的抗高血压药物一样有效，此外，还可发挥其降血压作用，并具有接近最佳的血流动力学改变。这些药物具有良好的耐受性和安全性，尽管它们在相当数量的患者中引起咳嗽。它们可以安全地与其他抗高血压药物联合使用，在大部分高血压人群中提供治疗获益。仅在双侧肾动脉狭窄或单肾狭窄时禁用ACE抑制剂。尽管迄今为止还没有前瞻性研究检查ACE抑制剂降低高血压心血管发病率和死亡率的能力，但这些药物的几个特征表明，这可能是因为ACE抑制剂在高血压中的几种作用具有潜在的肾保护和心脏保护作用。
This article examines the evidence justifying the use of angiotensin-converting enzyme (ACE) inhibitors as first-line antihypertensive drugs. ACE inhibitors are as effective as traditional antihypertensive agents and, in addition, exert their blood-pressure-lowering effect with near optimal hemodynamic alterations. These drugs have a good tolerance and safety profile although they induce cough in an appreciable number of patients. They can be safely associated with other antihypertensive agents to provide therapeutic benefit in a large proportion of the hypertensive population. ACE inhibitors are contraindicated only in bilateral renal artery stenosis or stenosis of a single kidney. Although to date no prospective study has examined the ability of ACE inhibitors to reduce cardiovascular morbidity and mortality in hypertension, several features of these drugs suggest that this may be the case as several effects of ACE inhibitors in hypertension are potentially nephroprotective and cardioprotective.